Journal
BLOOD ADVANCES
Volume 5, Issue 24, Pages 5490-5500Publisher
ELSEVIER
DOI: 10.1182/bloodadvances.2021004824
Keywords
-
Categories
Funding
- Fondazione Malattie del Sangue
- Rete Ematologica Lombarda
- AIRC [21352]
Ask authors/readers for more resources
Functional reserve of organs and systems plays a crucial role in predicting immunochemotherapy tolerance. Factors like age, comorbidities, and performance status are important in determining treatment feasibility and outcomes in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib. While age-related conditions may impact drug management, baseline ECOG-PS and neutropenia are the most accurate predictors of treatment feasibility and outcomes in this patient population.
Functional reserve of organs and systems is known to be relevant in predicting immunochemotherapy tolerance. Age and comorbidities, assessed by the cumulative illness rating scale (CIRS), have been used to address chemotherapy intensity. In the ibrutinib era, it is still unclear whether age, CIRS, and Eastern Cooperative Oncology Group performance status (ECOG-PS) retain their predictive role on treatment vulnerability. In this series of 712 patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib outside clinical trials, baseline ECOG-PS and neutropenia resulted as the most accurate predictors of treatment feasibility and outcomes. Age did not independently influence survival and ibrutinib tolerance, indicating that not age per se, but age-related conditions, may affect drug management. We confirmed the role of CIRS > 6 as a predictor of a poorer progression- and event-free survival (PFS, EFS). The presence of a severe comorbidity was significantly associated with permanent dose reductions (PDRs), not translating into worse outcomes. As expected, del(17p) and/or TP53(mut) and previous therapies affected PFS, EFS, and overall survival. No study so far has analyzed the influence of concomitant medications and CYP3A inhibitors with ibrutinib. In our series, these factors had no impact, although CYP3A4 inhibitors use correlated with Cox regression analysis, with an increased risk of PDR. Despite the limitation of its retrospective nature, this large study confirmed the role of ECOG-PS as the most accurate predictor of ibrutinib feasibility and outcomes, and importantly, neutropenia emerged as a relevant tool influencing patients' vulnerability. Although CIRS > 6 retained a significant impact on PFS and EFS, its value should be confirmed by prospective studies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available